Table 1.
Patients’ characteristics
| Characteristics | All patients (N = 133) | Enco/Cetux/Bini (N = 36) | Enco/Cetux (N = 97) |
|---|---|---|---|
| Sex, n (%) | |||
| Male | 55 (41) | 17 (47) | 38 (39) |
| Female | 78 (59) | 19 (53) | 59 (61) |
| Age (years), median (range) | 65 (26-85) | 64 (29-80) | 68 (26-85) |
| ECOG-PS, n (%) | |||
| 0 | 54 (40) | 18 (50) | 36 (37) |
| 1 | 61 (46) | 13 (36) | 48 (50) |
| 2 | 18 (14) | 5 (14) | 13 (13) |
| Location of primary tumor, n (%) | |||
| Left colon | 30 (23) | 10 (27) | 20 (21) |
| Rectum | 11 (8) | 2 (6) | 9 (9) |
| Right colon | 92 (69) | 24 (67) | 68 (70) |
| Involvement of three or more organs, n (%) | 53 (40) | 12 (33) | 41 (42) |
| Liver metastases | 76 (57) | 25 (69) | 51 (53) |
| Peritoneal metastases | 73 (55) | 18 (50) | 55 (57) |
| Primary tumor resected, n (%) | 104 (78) | 30 (83) | 74 (76) |
| Prior lines of therapy, n (%) | |||
| 0 | 4 (3) | 0 (0) | 4 (4) |
| 1 | 85 (64) | 22 (61) | 63 (65) |
| 2 | 34 (26) | 9 (25) | 25 (26) |
| 3 | 5 (4) | 2 (6) | 3 (3) |
| ≥4 | 5 (4) | 3 (8) | 2 (2) |
| Prior oxaliplatin, n (%) | 122 (92) | 34 (94) | 88 (91) |
| Prior anti-VEGF, n (%) | 109 (82) | 32 (89) | 77 (79) |
| Prior anti-EGFR, n (%) | 10 (8) | 5 (14) | 5 (5) |
| MSI status, n (%) | |||
| MSI high | 20 (15) | 7 (19) | 13 (13) |
| MSS | 111 (83) | 27 (75) | 84 (87) |
| Unknown | 2 (2) | 2 (6) | 0 (0) |
| Baseline CEA, n (%) | |||
| >5 μg/L | 93 (70) | 27 (75) | 66 (68) |
| ≤5 μg/L | 26 (19) | 3 (8) | 23 (24) |
| Unknown | 14 (11) | 6 (17) | 8 (8) |
| Baseline LDH, n (%) | |||
| ≥250 U/L | 39 (30) | 13 (36) | 26 (27) |
| <250 U/L | 43 (32) | 8 (22) | 35 (36) |
| Unknown | 51 (38) | 15 (42) | 36 (37) |
| Treatment received, n (%) | |||
| Enco/Cetux/Bini | 36 (27) | 36 (100) | 0 |
| Enco/Cetux | 97 (73) | 0 | 97 (100) |
| Time to metastasis, n (%) | |||
| Synchronous | 88 (66) | 22 (61) | 66 (68) |
| Metachronous | 45 (34) | 14 (39) | 31 (32) |
| Subsequent lines, n (%) | 47 (35) | 16 (44) | 31 (32) |
Bini, binimetinib; CEA, carcinoembryonic antigen; Cetux, cetuximab; EGFR, endothelial growth factor receptor; ECOG-PS, Eastern Cooperative Group Performance status; LDH, lactate dehydrogenase; MSI, microsatellite instability; MSS, microsatellite stable; Enco, encorafenib; N, number; VEGF, vascular endothelial growth factor.